SYBX
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 0.05 | $0 | -$563,000 |
| 2025 Q4 | 0.13 | $0 | -$923,000 |
| 2025 Q3 | -0.19 | $0 | -$1M |
| 2025 Q2 | -0.04 | $0 | -$399,000 |
| 2025 Q1 | 0.03 | $0 | -$2M |
| 2024 Q4 | -0.06 | $0 | -$568,000 |
| 2024 Q3 | -0.01 | $0 | -$648,000 |
| 2024 Q2 | 0.16 | $0 | -$15M |